

## PB 59 of 2023

# National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2023 (No. 6)

National Health Act 1953

I, SOUMYA SUDARSHAN, Assistant Secretary (Acting), Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care, make this Instrument under subsection 100(2) of the *National Health Act 1953*.

Date 29 June 2023

### **SOUMYA SUDARSHAN**

Assistant Secretary (Acting)
Pricing and PBS Policy Branch
Technology Assessment and Access Division

Content	ts		
	1	Name	1
	2	Commencement	1
	3	Authority	1
	4	Schedules	1
Schedule 1	—Ame	endments	2
	tional H B 79 of 2	ealth (Efficient Funding of Chemotherapy) Special Arrangement 2011 011)	2

#### 1 Name

- (1) This instrument is the *National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2023 (No. 6)*
- (2) This instrument may also be cited as PB 59 of 2023.

#### 2 Commencement

(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information									
Column 1	Column 2	Column 3							
Provisions	Commencement	Date/Details							
1. The whole of this instrument	1 July 2023	1 July 2023							

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

## 3 Authority

This instrument is made under subsection 100(2) of the National Health Act 1953.

#### 4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

# **Schedule 1—Amendments**

# National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (PB 79 of 2011)

[1] Part 1, Division 1, Section 3, definition for diluent fee

omit: \$5.59 substitute: \$5.77

[2] Part 1, Division 1, Section 3, definition for dispensing fee

*omit:* \$7.82 *substitute:* \$8.37

[3] Part 1, Division 1, Section 3, definition for distribution fee

omit: \$28.22 substitute: \$29.15

[4] Part 1, Division 1, Section 3, definition for preparation fee

omit: \$87.07 substitute: \$88.62

[5] Schedule 1, Part 1, after entry for Pemetrexed in the form Powder for I.V. infusion 1 g (as disodium)

insert:

Solution concentrate for I.V. infusion 100 mg (as disodium) in 4 mL	Injection	Pemetrexed Ever Pharma	IT	MP	D
Solution concentrate for I.V. infusion 500 mg (as disodium) in 20mL	Injection	Pemetrexed Ever Pharma	IT	MP	D
Solution concentrate for I.V. infusion 1 g (as disodium) in 40 mL	Injection	Pemetrexed Ever Pharma	IT	MP	D